CN1575191A - 用pde9抑制剂治疗胰岛素耐受性综合征和ⅱ型糖尿病 - Google Patents

用pde9抑制剂治疗胰岛素耐受性综合征和ⅱ型糖尿病 Download PDF

Info

Publication number
CN1575191A
CN1575191A CNA028211529A CN02821152A CN1575191A CN 1575191 A CN1575191 A CN 1575191A CN A028211529 A CNA028211529 A CN A028211529A CN 02821152 A CN02821152 A CN 02821152A CN 1575191 A CN1575191 A CN 1575191A
Authority
CN
China
Prior art keywords
alkyl
phenyl
group
halogen
heteroaryl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA028211529A
Other languages
English (en)
Chinese (zh)
Inventor
戴维·A·弗赖伯格
厄尔·M·吉布斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Products Inc
Original Assignee
Pfizer Products Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Products Inc filed Critical Pfizer Products Inc
Publication of CN1575191A publication Critical patent/CN1575191A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541—Non-condensed thiazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CNA028211529A 2001-11-02 2002-09-12 用pde9抑制剂治疗胰岛素耐受性综合征和ⅱ型糖尿病 Pending CN1575191A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US33698101P 2001-11-02 2001-11-02
US60/336,981 2001-11-02

Publications (1)

Publication Number Publication Date
CN1575191A true CN1575191A (zh) 2005-02-02

Family

ID=23318571

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA028211529A Pending CN1575191A (zh) 2001-11-02 2002-09-12 用pde9抑制剂治疗胰岛素耐受性综合征和ⅱ型糖尿病

Country Status (13)

Country Link
US (2) US6967204B2 (enExample)
EP (1) EP1444009A1 (enExample)
JP (1) JP2005508978A (enExample)
KR (1) KR20040053210A (enExample)
CN (1) CN1575191A (enExample)
BR (1) BR0213817A (enExample)
CA (1) CA2465632A1 (enExample)
HU (1) HUP0401998A2 (enExample)
IL (1) IL161155A0 (enExample)
MX (1) MXPA04004170A (enExample)
PL (1) PL370599A1 (enExample)
WO (1) WO2003037432A1 (enExample)
ZA (1) ZA200402173B (enExample)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103313988A (zh) * 2010-09-20 2013-09-18 英维沃医药有限公司 咪唑并三嗪酮化合物
CN104093720A (zh) * 2012-01-26 2014-10-08 H.隆德贝克有限公司 具有咪唑并三嗪酮骨架的pde9抑制剂
CN111183140A (zh) * 2017-05-26 2020-05-19 伊马拉公司 制备和使用pde9抑制剂的方法
US11608342B2 (en) 2015-07-07 2023-03-21 H. Lundbeck A/S PDE9 inhibitors with imidazo triazinone backbone and imidazo pyrazinone backbone for treatment of peripheral diseases

Families Citing this family (79)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1575916B1 (en) 2001-08-31 2013-05-22 The Rockefeller University Phosphodiesterase activity and regulation of phosphodiesterase 1-b-mediated signaling in brain
US20030195205A1 (en) * 2001-11-02 2003-10-16 Pfizer Inc. PDE9 inhibitors for treating cardiovascular disorders
KR20040053210A (ko) * 2001-11-02 2004-06-23 화이자 프로덕츠 인크. Ｐｄｅ9 억제제를 사용한 인슐린 저항 증후군 및 2형당뇨병의 치료
JP4467979B2 (ja) 2001-12-06 2010-05-26 メルク・シャープ・エンド・ドーム・コーポレイション 有糸分裂キネシン阻害剤
ES2280596T3 (es) * 2001-12-29 2007-09-16 Novo Nordisk A/S Uso combinado de un compuesto de glp-1 y un inhibidor de una aldosa reductasa.
IS1935B (is) * 2002-03-19 2004-06-16 Actavis Group Hf. Fósínópríl lyfjasamsetning
ATE478872T1 (de) * 2002-03-28 2010-09-15 Ustav Ex Botan Av Cr V V I I O Pyrazoloä4,3-düpyrimidine, verfahren zu ihrer herstellung und therapeutische anwendung
DE10238722A1 (de) 2002-08-23 2004-03-11 Bayer Ag Selektive Phosphodiesterase 9A-Inhibitoren als Arzneimittel zur Verbesserung kognitiver Prozesse
DE10238723A1 (de) * 2002-08-23 2004-03-11 Bayer Ag Phenyl-substituierte Pyrazolyprimidine
DE10238724A1 (de) * 2002-08-23 2004-03-04 Bayer Ag Alkyl-substituierte Pyrazolpyrimidine
US20040220186A1 (en) * 2003-04-30 2004-11-04 Pfizer Inc. PDE9 inhibitors for treating type 2 diabetes,metabolic syndrome, and cardiovascular disease
WO2004099211A1 (de) * 2003-05-09 2004-11-18 Bayer Healthcare Ag 6-cyclylmethyl- und 6-alkylmethyl-substituierte pyrazolopyrimidine
DE10320785A1 (de) * 2003-05-09 2004-11-25 Bayer Healthcare Ag 6-Arylmethyl-substituierte Pyrazolopyrimidine
US8044060B2 (en) 2003-05-09 2011-10-25 Boehringer Ingelheim International Gmbh 6-cyclylmethyl- and 6-alkylmethyl pyrazolo[3,4-D]pyrimidines, methods for their preparation and methods for their use to treat impairments of perception, concentration learning and/or memory
DE102004004142A1 (de) * 2003-05-09 2004-11-25 Bayer Healthcare Ag 6-Cyclylmethyl- und 6-Alkylmethyl-substituierte Pyrazolopyrimidine
BRPI0416118A (pt) * 2003-10-31 2007-01-02 Pfizer Prod Inc inibição da fosfodiesterase 9 como tratamento para estados relacionados com a obesidade
US20080125403A1 (en) 2004-04-02 2008-05-29 Merck & Co., Inc. Method of Treating Men with Metabolic and Anthropometric Disorders
EP1751133B1 (en) * 2004-04-28 2010-04-14 Vertex Pharmaceuticals Incorporated Compositions useful as inhibitors of rock and other protein kinases
US8673964B2 (en) 2004-05-20 2014-03-18 Diamedica Inc. Use of drug combinations for treating insulin resistance
CN101198614B (zh) 2005-06-14 2011-07-06 Aska制药株式会社 噻吩并嘧啶衍生物
EP1919287A4 (en) * 2005-08-23 2010-04-28 Intra Cellular Therapies Inc ORGANIC COMPOUNDS FOR TREATING A REDUCED DOPAMINE RECEPTOR SIGNALING ACTIVITY
KR101419075B1 (ko) * 2006-08-08 2014-07-11 아스카 세이야쿠 가부시키가이샤 퀴나졸린 유도체
MEP8509A (en) 2006-09-07 2011-12-20 Combination treatment for diabetes mellitus
EP2066355A2 (en) * 2006-09-19 2009-06-10 Braincells, Inc. Combination comprising a peroxisome proliferator activated receptor agent and a second neurogenic agent for treating a nervous system disorder, increasing neurodifferentiation and increasing neurogenesis
WO2008072779A1 (ja) 2006-12-13 2008-06-19 Aska Pharmaceutical Co., Ltd. キノキサリン誘導体
AU2007332439A1 (en) * 2006-12-13 2008-06-19 Aska Pharmaceutical Co., Ltd. Therapeutic agent for urinary tract disease
ITMI20070140A1 (it) * 2007-01-30 2008-07-31 Campagnolo Srl Dispositivo di interazione uomo-bicicletta
WO2008124505A2 (en) * 2007-04-05 2008-10-16 Ironwood Pharmaceuticals,Inc. Soluble guanylate cyclase (sgc) modulators for treatment of lipid related disorders
PT2152712E (pt) * 2007-05-11 2012-02-29 Pfizer Compostos amino-heterocíclicos
PT2152663E (pt) 2007-06-04 2014-06-03 Univ Ben Gurion Compostos de triarilo e composições que compreendem os mesmos
US8648085B2 (en) 2007-11-30 2014-02-11 Boehringer Ingelheim International Gmbh 1, 5-dihydro-pyrazolo (3, 4-D) pyrimidin-4-one derivatives and their use as PDE9A mudulators for the treatment of CNS disorders
KR20100121527A (ko) 2008-02-29 2010-11-17 콘서트 파마슈티컬즈, 인크. 치환된 잔틴 유도체
UA105362C2 (en) 2008-04-02 2014-05-12 Бьорингер Ингельхайм Интернациональ Гмбх 1-heterocyclyl-1, 5-dihydro-pyrazolo [3, 4-d] pyrimidin-4-one derivatives and their use as pde9a modulators
CN102143965A (zh) 2008-09-08 2011-08-03 贝林格尔.英格海姆国际有限公司 吡唑并嘧啶酮及其在治疗中枢神经系统疾病中的用途
US8410284B2 (en) 2008-10-22 2013-04-02 Merck Sharp & Dohme Corp Cyclic benzimidazole derivatives useful as anti-diabetic agents
WO2010051206A1 (en) 2008-10-31 2010-05-06 Merck Sharp & Dohme Corp. Novel cyclic benzimidazole derivatives useful anti-diabetic agents
TWI404721B (zh) 2009-01-26 2013-08-11 Pfizer 胺基－雜環化合物
US20110053961A1 (en) 2009-02-27 2011-03-03 Concert Pharmaceuticals, Inc. Substituted xanthine derivatives
UY32531A (es) 2009-03-31 2010-10-29 Boehringer Ingelheim Int Nuevos compuestos para el tratamiento de trastornos del snc
WO2011016861A2 (en) 2009-08-05 2011-02-10 Intra-Cellular Therapies, Inc. Novel regulatory proteins and inhibitors
AR078793A1 (es) 2009-10-27 2011-12-07 Orion Corp Derivados de carboxamidas no esteroidales y acil hidrazona moduladores de receptores androgenicos de tejido selectivo (sarm), composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento del cancer de prostata entre otros
JP2013520502A (ja) 2010-02-25 2013-06-06 メルク・シャープ・エンド・ドーム・コーポレイション 有用な抗糖尿病薬である新規な環状ベンズイミダゾール誘導体
BR112013003097B1 (pt) 2010-08-12 2021-03-16 Boehringer Ingelheim International Gmbh 6-cicloalquil-pirazolopirimidinonas e composição farmacêutica
ES2583528T3 (es) 2010-09-07 2016-09-21 Astellas Pharma Inc. Compuesto de pirazoloquinolina
US8809345B2 (en) 2011-02-15 2014-08-19 Boehringer Ingelheim International Gmbh 6-cycloalkyl-pyrazolopyrimidinones for the treatment of CNS disorders
CA2826649C (en) 2011-02-25 2016-07-26 Merck Sharp & Dohme Corp. Novel cyclic azabenzimidazole derivatives useful as anti-diabetic agents
US20140296263A1 (en) 2011-07-19 2014-10-02 Concert Pharmaceuticals, Inc. Substituted xanthine derivatives
MX381326B (es) 2011-10-10 2025-03-12 H Lundbeck As Derivados de 7h-imidazo[1-5-a]pirazin-8-ona como inhibidores de la fosfodiesterasa 9(pde9); y el uso de los mismos en el tratamiento de trastornos neurodegenerativos
EP2828262A4 (en) 2012-03-19 2015-09-23 Forum Pharmaceuticals Inc IMIDAZOTRIAZINONVERBINDUNGEN
US20130315891A1 (en) 2012-05-25 2013-11-28 Matthew Charles Formulations of human tissue kallikrein-1 for parenteral delivery and related methods
US20130323222A1 (en) 2012-06-04 2013-12-05 Matthew Charles Human tissue kallikrein 1 glycosylation isoforms
US20140045746A1 (en) 2012-08-02 2014-02-13 Merck Sharp & Dohme Corp. Antidiabetic tricyclic compounds
WO2014024125A1 (en) 2012-08-08 2014-02-13 Celon Pharma S.A. Pyrazolo[4,3-d]pyrimidin-7(6h)-one derivatives as pde9 inhibitors
CN102786525B (zh) 2012-08-08 2014-12-17 中山大学 N-取代吡唑并[3,4-d]嘧啶酮类化合物、其制备方法及其应用
JP2016516004A (ja) 2013-02-22 2016-06-02 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． 抗糖尿病二環式化合物
WO2014139388A1 (en) 2013-03-14 2014-09-18 Merck Sharp & Dohme Corp. Novel indole derivatives useful as anti-diabetic agents
JP2015067538A (ja) * 2013-09-26 2015-04-13 株式会社アイエイアイ 血糖値降下剤
WO2015051496A1 (en) 2013-10-08 2015-04-16 Merck Sharp & Dohme Corp. Antidiabetic tricyclic compounds
EP3065723B1 (en) 2013-11-05 2020-09-23 Ben Gurion University of the Negev Research and Development Authority Compounds for the treatment of diabetes and disease complications arising from same
WO2015160913A1 (en) 2014-04-18 2015-10-22 Concert Pharmaceuticals, Inc. Methods of treating hyperglycemia
US20180072741A1 (en) 2016-09-09 2018-03-15 Incyte Corporation Pyrazolopyrimidine compounds and uses thereof
US20180072718A1 (en) 2016-09-09 2018-03-15 Incyte Corporation Pyrazolopyridine compounds and uses thereof
AR109596A1 (es) 2016-09-09 2018-12-26 Incyte Corp Compuestos pirazolopiridina y sus usos
WO2018106518A1 (en) 2016-12-06 2018-06-14 Merck Sharp & Dohme Corp. Antidiabetic heterocyclic compounds
WO2018118670A1 (en) 2016-12-20 2018-06-28 Merck Sharp & Dohme Corp. Antidiabetic spirochroman compounds
WO2018152220A1 (en) 2017-02-15 2018-08-23 Incyte Corporation Pyrazolopyridine compounds and uses thereof
AU2018230478B2 (en) 2017-03-09 2025-01-23 Diamedica Inc. Dosage forms of tissue kallikrein 1
JP2020523309A (ja) 2017-06-08 2020-08-06 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． ピラゾロピリミジンｐｄｅ９インヒビター
US10722495B2 (en) 2017-09-08 2020-07-28 Incyte Corporation Cyanoindazole compounds and uses thereof
US10745388B2 (en) 2018-02-20 2020-08-18 Incyte Corporation Indazole compounds and uses thereof
US10752635B2 (en) 2018-02-20 2020-08-25 Incyte Corporation Indazole compounds and uses thereof
DK3755703T3 (da) 2018-02-20 2022-06-27 Incyte Corp N-(phenyl)-2-(phenyl)pyrimidin-4-carboxamidderivater og relaterede forbindelser som hpk1-inhibitorer til behandling af kræft
US11299473B2 (en) 2018-04-13 2022-04-12 Incyte Corporation Benzimidazole and indole compounds and uses thereof
BR112020024019A2 (pt) 2018-05-25 2021-02-23 Imara Inc. monoidrato e formas cristalinas de 6-[(3s,4s)-4-metil-1-(pirimidin-2-ilmetil)pirrolidin-3-il]-3-tetra-hidropiran-4-il-7h-imidazo[1,5-a]pirazin-8-ona
US10899755B2 (en) 2018-08-08 2021-01-26 Incyte Corporation Benzothiazole compounds and uses thereof
KR20250108770A (ko) 2018-08-31 2025-07-15 카듀리온 파마슈티칼스, 인크. 겸상 세포 질환의 치료를 위한 pde9 억제제
WO2020068729A1 (en) 2018-09-25 2020-04-02 Incyte Corporation Pyrazolo[4,3-d]pyrimidine compounds as alk2 abd/or fgfr modulators
KR20220059480A (ko) 2019-08-06 2022-05-10 인사이트 코포레이션 고체 형태의 hpk1 억제제
JP2023550269A (ja) * 2020-10-27 2023-12-01 カーデュリオン・ファーマシューティカルズ・インコーポレイテッド 心不全を治療するためのｐｄｅ９阻害剤

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4666908A (en) * 1985-04-05 1987-05-19 Warner-Lambert Company 5-Substituted pyrazolo[4,3-d]pyrimidine-7-ones and methods of use
DE19541264A1 (de) 1995-11-06 1997-05-07 Bayer Ag Purin-6-on-derivate
EP0882718B1 (en) * 1995-12-28 2005-08-31 Fujisawa Pharmaceutical Co., Ltd. Benzimidazole derivatives
GB9722520D0 (en) * 1997-10-24 1997-12-24 Pfizer Ltd Compounds
US6444816B1 (en) * 1997-10-27 2002-09-03 Dr. Reddy's Research Foundation Fused 7-oxo-pyrimidinyl compounds, preparation, composition and use thereof
US5922595A (en) * 1997-12-09 1999-07-13 Incyte Pharmaceuticals, Inc. Cyclic GMP phosphodiesterase
US6225456B1 (en) 1998-05-07 2001-05-01 University Technololy Corporation Ras suppressor SUR-5
AU6189999A (en) 1998-10-15 2000-05-08 Bioimage A/S Specific therapeutic interventions obtained by interference with redistribution and/or targetting
HUP0300725A3 (en) * 2000-08-11 2005-11-28 Pfizer Treatment of the insulin resistance syndrome with selective cgmp pde5 inhibitors
EP1355651A2 (en) * 2001-02-02 2003-10-29 Pfizer Limited Treatment of diabetes mellitus using vardenafil
AUPR576801A0 (en) 2001-06-19 2001-07-12 University Of Tasmania Methods and pharmaceuticals for treating muscle insulin resistance and related conditions
KR20040053210A (ko) * 2001-11-02 2004-06-23 화이자 프로덕츠 인크. Ｐｄｅ9 억제제를 사용한 인슐린 저항 증후군 및 2형당뇨병의 치료
US20040220186A1 (en) * 2003-04-30 2004-11-04 Pfizer Inc. PDE9 inhibitors for treating type 2 diabetes,metabolic syndrome, and cardiovascular disease

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103313988A (zh) * 2010-09-20 2013-09-18 英维沃医药有限公司 咪唑并三嗪酮化合物
CN103313988B (zh) * 2010-09-20 2016-06-08 论坛医药有限公司 咪唑并三嗪酮化合物
CN104093720A (zh) * 2012-01-26 2014-10-08 H.隆德贝克有限公司 具有咪唑并三嗪酮骨架的pde9抑制剂
CN104093720B (zh) * 2012-01-26 2017-04-12 H.隆德贝克有限公司 具有咪唑并三嗪酮骨架的pde9抑制剂
CN107082783A (zh) * 2012-01-26 2017-08-22 H.隆德贝克有限公司 具有咪唑并三嗪酮骨架的pde9抑制剂
CN107082783B (zh) * 2012-01-26 2019-03-22 H.隆德贝克有限公司 具有咪唑并三嗪酮骨架的pde9抑制剂
US11608342B2 (en) 2015-07-07 2023-03-21 H. Lundbeck A/S PDE9 inhibitors with imidazo triazinone backbone and imidazo pyrazinone backbone for treatment of peripheral diseases
CN111183140A (zh) * 2017-05-26 2020-05-19 伊马拉公司 制备和使用pde9抑制剂的方法
CN111183140B (zh) * 2017-05-26 2022-12-02 伊马拉公司 制备和使用pde9抑制剂的方法
CN115746003A (zh) * 2017-05-26 2023-03-07 伊马拉公司 制备和使用pde9抑制剂的方法
US11999741B2 (en) 2017-05-26 2024-06-04 Cardurion Pharmaceuticals, Inc. Process for the synthesis of 6-((3S,4S)-4-methyl-1-(pyrimidin-2-ylmethyl)pyrrolidin-3-yl)-3-(tetrahydropyran-4-yl-7H-imidazo[1,5-a]pyrazin-8-one

Also Published As

Publication number Publication date
HUP0401998A2 (hu) 2005-01-28
BR0213817A (pt) 2004-10-19
JP2005508978A (ja) 2005-04-07
WO2003037432A1 (en) 2003-05-08
IL161155A0 (en) 2004-08-31
ZA200402173B (en) 2005-03-18
CA2465632A1 (en) 2003-05-08
EP1444009A1 (en) 2004-08-11
KR20040053210A (ko) 2004-06-23
US20040023989A1 (en) 2004-02-05
US20050070557A1 (en) 2005-03-31
MXPA04004170A (es) 2004-09-06
PL370599A1 (en) 2005-05-30
US6967204B2 (en) 2005-11-22

Similar Documents

Publication Publication Date Title
US6967204B2 (en) Treatment of insulin resistance syndrome and type 2 diabetes with PDE9 inhibitors
CN1204138C (zh) 吡唑并[4,3－d]嘧啶衍生物
CN1297555C (zh) Mcp－1功能的拮抗物及其使用方法
JP6130398B2 (ja) 新規アゼチジン誘導体、その医薬組成物及び使用
US20090203676A1 (en) G-protein Coupled Receptor Agonists
CN1738797A (zh) 取代的芳基硫脲和相关的化合物,病毒复制的抑制剂
CN1547583A (zh) 多环鸟嘌呤磷酸二酯酶v抑制剂
CN1897936A (zh) 环状胍、含有这种化合物的组合物及其使用方法
CN1460105A (zh) 黄嘌呤磷酸二酯酶v抑制剂
CN87107875A (zh) 四氢化萘衍生物
CN1659148A (zh) 芳基肟化合物
CN1809351A (zh) Akt活性抑制剂
CN1234031A (zh) 吲唑衍生物及其作为磷酸二酯酶(pde)iv型和肿瘤坏死因子(tnf)产生的抑制剂的应用
CN101031561A (zh) 可以用作凝血因子xa抑制剂的羰基化合物
CN1826111A (zh) 用于治疗变应性和过增生性疾病的咪唑衍生物
CN1678608A (zh) 新的神经肽yy5受体拮抗剂
CN1922156A (zh) 作为钠通道阻断剂的取代的三唑
CN1863803A (zh) 嘧啶衍生物
CN1839131A (zh) 吡咯烷甲腈类化合物及其作为dpp－iv抑制剂的应用
CN1942463A (zh) 2－氨基嘧啶衍生物
CN100345823C (zh) 化合物、组合物及方法
CN1717409A (zh) 吡唑并二氮杂萘衍生物
HK1069551A (en) Treatment of insulin resistance syndrome and type 2 diabetes with pde9 inhibitors
CN1274655C (zh) 新的3－芳基－2,5－二羟基－1,4－苯醌类化合物,其制备方法以及包含其的药物组合物
CN1761656A (zh) 作为nep抑制剂的3－(1－[3－(1,3－苯并噻唑－6－基)丙基氨基甲酰基]环烷基)丙酸衍生物

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1069551

Country of ref document: HK

C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication
REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1069551

Country of ref document: HK